U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847281) titled 'A Study of AK157D1 for Injection in Advanced Solid Tumors' on Sept. 21.
Brief Summary: This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK157D1 for injection in advanced solid tumors.
Study Start Date: Sept. 21
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: AK157D1 for injection
IV infusion, administered on Day 1 of each cycle, Q3W, continuous treatment
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Akeso
Published by HT Digital Content Services with permission from Health Daily Digest...